Position in ABVX
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$1,221,327
New position
Shares Held
9,165
first reported quarter
Ownership
0.011%
of shares outstanding
% of Portfolio
0.42%
of 13F equity value
Holder Rank
#161
of 302 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026IRIDIAN ASSET MANAGEMENT LLC/CT holds $54,664,937 across 7 Biotechnology names. ABVX ranks #6 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PGEN |
Precigen, Inc.
|
4,031,963 | $22,982,189 | |
| 2 | NVCT |
Nuvectis Pharma, Inc.
|
777,078 | $14,290,464 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
47,924 | $11,730,357 | |
| 4 | NKTR |
Nektar Therapeutics
|
38,802 | $2,708,767 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
27,689 | $1,521,233 | |
| 6 | ABVX |
Abivax S.A.
This page
|
9,165 | $1,221,327 | |
| 7 | BCTX |
BriaCell Therapeutics Corp.
|
65,000 | $210,600 |
All Filings in ABVX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,221,327 | 9,165 | Shares | Sole | 2026-07-29 | |
| No filing history on record for this holder in this stock. | ||||||